title: Effects of bisphosphonate on bone metabolism in tail-suspended rats.
abstract: Our previous studies demonstrated that tail suspension causes early, transient increases in osteoclastic activity, followed by a decrease in osteoblastic activity in the hind limbs of rats. To assess whether this early increase in bone resorption is important in the development of disuse atrophy, the effect of YH529, a third generation bisphosphonate, was studied on hind limb atrophy in rats subjected to tail suspension. YH529 (YH group) or PBS (control group) were administered subcutaneously in 5-week-old male Wistar rats suspended for 7 days. In the control group, wet weight, calcium and phosphorus contents decreased significantly in the femur but they did not change in the humerus. In the YH group, however, these parameters did not change significantly in the femur, but both calcium and phosphorus increased significantly in the humerus. These results indicate that the inhibition of bone resorption by YH529 prevents the development of disuse atrophy induced by tail suspension. It is thus suggested that early increases in bone resorption are important for the development of disuse bone atrophy.
authors.affiliation: Department of Endocrinology and Metabolism, Division of Molecular and Cellular Adaptation, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kurokouchi
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: S
authors.initials: S
authors.lastname: Ohmori
authors.forename: K
authors.initials: K
authors.lastname: Kanda
authors.forename: Y
authors.initials: Y
authors.lastname: Murata
authors.forename: R
authors.initials: R
authors.lastname: Izumi
authors.forename: M
authors.initials: M
authors.lastname: Inazu
authors.forename: H
authors.initials: H
authors.lastname: Iwata
authors.forename: H
authors.initials: H
authors.lastname: Seo
mesh_terms: D000818:Animals; D018488:Bone Demineralization, Pathologic / Q000378:metabolism / Q000517:prevention & control; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D001862:Bone Resorption / Q000378:metabolism / Q000517:prevention & control*; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D002118:Calcium / Q000097:blood / Q000378:metabolism; D004164:Diphosphonates / Q000494:pharmacology* / Q000627:therapeutic use; D005269:Femur / Q000187:drug effects / Q000378:metabolism*; D019417:Hindlimb Suspension; D006811:Humerus / Q000187:drug effects / Q000378:metabolism*; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D010758:Phosphorus / Q000097:blood / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D018474:Weightlessness Simulation
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; C087958:YM 529; D010758:Phosphorus; D002118:Calcium